ABOS
Price
$1.04
Change
-$0.01 (-0.95%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
63.6M
Earnings call today
ARVN
Price
$6.27
Change
-$0.25 (-3.83%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
475.9M
79 days until earnings call
Ad is loading...

ABOS vs ARVN

Header iconABOS vs ARVN Comparison
Open Charts ABOS vs ARVNBanner chart's image
Acumen Pharmaceuticals
Price$1.04
Change-$0.01 (-0.95%)
Volume$3.82K
Capitalization63.6M
Arvinas
Price$6.27
Change-$0.25 (-3.83%)
Volume$55.48K
Capitalization475.9M
ABOS vs ARVN Comparison Chart
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABOS vs. ARVN commentary
May 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and ARVN is a Hold.

Ad is loading...
COMPARISON
Comparison
May 14, 2025
Stock price -- (ABOS: $1.05 vs. ARVN: $6.52)
Brand notoriety: ABOS and ARVN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 78% vs. ARVN: 72%
Market capitalization -- ABOS: $63.6M vs. ARVN: $475.9M
ABOS [@Biotechnology] is valued at $63.6M. ARVN’s [@Biotechnology] market capitalization is $475.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileARVN’s FA Score has 1 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • ARVN’s FA Score: 1 green, 4 red.
According to our system of comparison, ARVN is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 6 TA indicator(s) are bullish while ARVN’s TA Score has 3 bullish TA indicator(s).

  • ABOS’s TA Score: 6 bullish, 2 bearish.
  • ARVN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than ARVN.

Price Growth

ABOS (@Biotechnology) experienced а +0.96% price change this week, while ARVN (@Biotechnology) price change was -14.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.49%. For the same industry, the average monthly price growth was +10.87%, and the average quarterly price growth was -7.60%.

Reported Earning Dates

ABOS is expected to report earnings on Aug 18, 2025.

ARVN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARVN($476M) has a higher market cap than ABOS($63.6M). ABOS YTD gains are higher at: -38.953 vs. ARVN (-65.989). ABOS has higher annual earnings (EBITDA): -77.89M vs. ARVN (-243.6M). ARVN has more cash in the bank: 1.04B vs. ABOS (200M). ARVN has less debt than ABOS: ARVN (9.7M) vs ABOS (28.5M). ARVN has higher revenues than ABOS: ARVN (263M) vs ABOS (0).
ABOSARVNABOS / ARVN
Capitalization63.6M476M13%
EBITDA-77.89M-243.6M32%
Gain YTD-38.953-65.98959%
P/E RatioN/AN/A-
Revenue0263M-
Total Cash200M1.04B19%
Total Debt28.5M9.7M294%
FUNDAMENTALS RATINGS
ARVN: Fundamental Ratings
ARVN
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSARVN
RSI
ODDS (%)
Bullish Trend 6 days ago
69%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 14 days ago
77%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
66%
View a ticker or compare two or three
Ad is loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA318.3820.12
+6.75%
Tesla
AAPL210.7912.52
+6.31%
Apple
SPY582.9918.65
+3.30%
SPDR® S&P 500® ETF
GME28.050.51
+1.85%
GameStop Corp
BTC.X102812.950000-1293.406200
-1.24%
Bitcoin cryptocurrency

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with ATOS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then ATOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+7.13%
ATOS - ABOS
56%
Loosely correlated
+2.47%
CRBU - ABOS
49%
Loosely correlated
+5.66%
ABCL - ABOS
48%
Loosely correlated
+1.48%
BEAM - ABOS
47%
Loosely correlated
+4.77%
FHTX - ABOS
47%
Loosely correlated
+5.48%
More

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with ATXS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
-1.36%
ATXS - ARVN
39%
Loosely correlated
+3.31%
ERAS - ARVN
39%
Loosely correlated
N/A
ABOS - ARVN
38%
Loosely correlated
+7.13%
CRGX - ARVN
36%
Loosely correlated
+1.24%
CRBU - ARVN
36%
Loosely correlated
+5.66%
More